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 ABSTRACT                                                                                                                                            
Screening for phenylketonuria and galactosemia 
among Egyptian newborns in Menoufiya governorate
Hanaa El Araby¹, Ekram Fateen² and Amr Gouda3
¹Pediatrics Department, National Liver Institute, Menoufiya University, ²Head 
of Biochemical Genetics Department, 3Biochemical Genetics Department, 
National Research Center, Egypt.
Aim of the Work: Was to study the prevalence of phenylketonuria and galac-
tosemia in Menoufiya Governorate newborns. Among 3000 newborns, their 
mean ages were 9.3±2.43 days; mean weight was 3.1 ±0.82 Kg.  Among them 
1800( 60% ) males and 1200 (40% ) females who attended the central hospital 
and medical units for BCG vaccination in the duration from March 2005 to 
May 2008.   
Results: The results showed that  the  mean of phenylalanine level 
was 3.19 ±1.82 mg/dl and the mean total galactose level was 3.34 ± 2.23mg/
dl, among the 3000 neonates, 2183 (72.8. %) had phenylalanine levels ranging 
from 2-5 mg /dl, 705 (23.5%) had  levels ranging from 5-7 mg/dl, 111(3.7%) 
had  levels  ranging from 7-10 mg/dl   and one newborn (0.033%) had phenyl-
alanine level of 22 mg/dl. The results for galactosemia screening assay showed 
that 2528 neonates (84.3%) had galactose levels ranging from 2-6 mg/dl, 450 
(15%) had levels ranging from 6-8 mg/dl, 21(0.7%) had  levels ranging from 
8-12 mg/dl and one newborn (0.033%) had galactose level of 19 mg/dl. The 
child was reassayed and was found to be true hypergalactosemia 120mg/dl. 
Conclusion: We concluded that the prevalence of each of phenylketonuria and 
galactosemia in Menoufiya Governorate in the 3000 newborn tested was 1/3000 
(0.03%). So, we estimate that about 333 neonates are affected every year with 
PKU and 333 with galactosemia as one million babies are born yearly, which 
could be prevented. The prevention of such treatable disorders depends on 
planning an efficient screening programme especially within three weeks after 
birth. So we recommend multicenter studies to encourage national neonatal 
screening programmes specialy for these treatable diseases. 






INTRODUCTION                             
Neonatal screening programmes for 
PKU and galactosemia were introduced 
in many European and North American 
countries about 30 years ago. To prevent 
disability and handicapped through sim-
ple tests and subsequent dietary treat-
ment1. If undiagnosed and untreated, 
many of the affected children will be 
hospitalized for extensive periods and 
require intensive care. There will be a 
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major impact on the families concerned 
and on health care provision.2
Phenylketonuria (PKU) is an autoso-
mal-recessive disorder most commonly 
caused by a mutation in the gene cod-
ing for phenylalanine hydroxylase, an 
enzyme responsible for the conversion 
of phenylalanine to tyrosine. Sustained 
phenylalanine concentrations higher 
than 20 mg per dl usually correlate with 
classic symptoms of PKU.3
Unless the condition is detected and 
treatment is initiated soon after birth, 
phenylalanine builds up in the blood 
and body tissues and is toxic to the 
brain, usually resulting in severe men-
tal retardation left to clinical ascertain-
ment, diagnosis is often late and may be 
difficult to achieve. Frequently severe 
physical, developmental and neurologi-
cal damage has occurred or begun by 
the time of diagnosis. It is characterized 
by hyperphenylalaninemia and mani-
fest primarily as neurological damage.4
Infants with PKU appear normal at birth 
and have fair skin and hairs than other 
members of their family. Untreated 
PKU patients usually first become no-
ticeable between 6 to 12 months of age, 
by which time up to 50 I Q points will 
have been lost5. This mental retardation 
may be associated with microcephaly, 
seizures, eczema, delayed speech, be-
havier abnormalities, gait disturbance 
and even autism.6
Only rarely, symptoms lead to diagno-
sis before this stage. Effective therapy 
to lower raised blood phenylalanine 
levels by dietary restriction of phenylal-
anine prevents progressive, irreversible 
brain damage but does not reverse pre-
existing damage. The early treatment 
is commenced for the better ultimate 
outcome. Most early treated children 
with PKU fall within the normal range 
of ability and attend ordinary schools.7
Reports of neurological deterioration 
in young adults off dietary supervi-
sion have led to the recommendation of 
treatment supervision for life.8
Galactose is the major sugar found in 
milk. It is normally converted to glu-
cose, another simple sugar, but in ga-
lactosemia, the enzymes needed for this 
conversions (galactose-1-phosphate 
uridyltransferase GALT, galactoki-
nase GALK and galactose epimerase 
GALE)) are missing. Galactose accu-
mulates in and damages the body’s cells 
and organs. Clinical manifestations of 
galactosemia include lethargy, hypoto-
nia, jaundice, hypoglycemia, elevated 
liver enzymes and coagulopathy, severe 
mental retardation, growth defeciency, 
overwhelming infection and death.9
It is important to distinguish the galac-
tosemia disease genotype (G/G) from 
asymptomatic variant genotypes (e.g., 
G/D, G/N, D/D), which can be picked 
up as “positive” in newborn screening. 
Galactosemia is treated by excluding 
milk and milk products from the diet. 
Children treated with this special diet 
usually show satisfactory general health 
and growth. But most patients develop 
abnormalities despite dietary treat-
ment.3
Infants with classical galactosemia, who 
have near total absence of GALT activ-
ity, exposure to dietary galactose results 
in acute deterioration of multiple organ 
systems, including liver dysfunction, 
coagulopathy, poor feeding and weight 
loss, renal tubular dysfunction, cere-
bral edema, vitreous hemorrhage and 
Escherichia coli sepsis and even death. 
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This “neonatal toxicity syndrome” can 
be reversed by withdrawal of dietary 
galactose. So most national screening 
programs have included galactosemia 
in their newborn screening programs, 
anticipating that early detection and 
intervention would prevent long-term 
complications such as mental retarda-
tion, premature ovarian failure which 
is nearly universal in females with ga-
lactosemia, speech delay and cerebellar 
symptoms.10
Cataract has been observed within few 
days after birth. Some patients have 
more chronic course with presentation 
few months after birth with delayed 
development, hepatomegaly and cata-
racts.
Early introduction of a galactose free 
diet will cause the resolution of few 
manifestations of the disease, including 
cataract and prevent their recurrence. 
Unfortunately this has not proven to be 
true, probably because of the signifi-
cant endogenous turnover of galactose 
which is independent of manipulation 
of dietary intake.11
There are different views in the litera-
tures of the value of neonatal screen-
ing for galactosemia for a number of 
reasons: there is little evidence that 
the early institution of treatment al-
lowed by neonatal screening improve 
long term outcome12-14. The long term 
outcome remains poor inspite of best 
available current treatment and there 
are yet uncosted difficulties and un-
certainties posed by the allelic variants 
producing GALT deficiency.15
Hypergalactosaemia identified by 
neonatal mass screening has several 
aetiologies, including portosystemic 
shunt16-20. Recently it has been reported 
that citrin deficiency also causes hyper-
galactosaemia in infancy21-23. Thus hy-
pergalactosaemia should not be thought 
of solely in terms of possible enzyme 
deficiency, but also as a reflection of 
portosystemic shunt or liver dysfunc-
tion, e.g. citrin deficiency and Fan-
coni-Bickel syndrome. However, the 
incidence of these different causes of 
hypergalactosaemia has not been deter-
mined11. The benefits of screening are 
currently related to the possible preven-
tion of acute neonatal illness in some 
cases, the facilitation of collection of 
epidemiological and outcome data and 
improved patient support. 
PATIENTS AND METHODS                         
The study included 3000 newborns, 
their mean  ages was 9.3 ± 2.43 days, 
mean weight was 3.1 ± 0.82 Kg, among 
them 1800 (60%) males and 1200 
(40%) females who attended the cen-
tral hospital and medical units for BCG 
vaccination in Menoufiya Governorate 
from March 2006 to May 2008.  
Every newborn was subjected to: 
Through history using special card as 
shown below (Fig. 1):-
* Birth date.
* Date of sampling.
* Governorate. 
* Code number for every sample ei-




 Single or twin.
 Full mother name.
 Address and telephone.
 Site of birth (hospital, private clinic 
or home birth).
167
El Araby et al.
Fig. 1: Card used record to cases in the study.
Clinical examination including: Weight, 
length, head circumference, presence 
of jaundice, suckling, Moro reflex and 
systematic examination of chest, heart 
and abdomen.
From each newborn a heel prick was 
taken after sterilization and a sample of 
blood of 1 cm in diameter is absorbed 
on filter paper (Schleucher and Schlaull 
903 = S & S 903) which is specific fil-
ter papers for neonatal screening, left to 
dry and then two punches were taken 
(Fig. 2) using specific puncher with cer-
tain diameter for phenylalanine (6 mm) 
and total galactose assay (4 mm) using 
quantitative colorimetric enzyme assay 
test.
Fig. 2: Size of punches for PKU and for galactosemia.
A- Determination of the amount of 
phenylalanine in dried blood spot 
using Quantitative Colorimetric En-
zyme Assay test:
1. 6 mm diameter blood spot is 
punched into the ELISA plates 
well from each sample. 200 ul 3% 
trichloroacetic acid. Standard and 
controls should be punched in du-
plicate.
2. Incubate for 30 – 60 minutes at 18 
– 26ºC. 
3. Pipette 15 μl of 0.5 M NaOH 
solution  into the wells of a clean 
flat bottom microtitration plate 
4. Add 80 μl of each blood spot elu-
ate or standards, controls and speci-
mens to the wells cotaining 15 μl 
0.5 M NaOH.
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5. Add 100 μl working enzyme re-
agent to each well, mix and incu-
bate for 30 minutes at 18 – 25ºC.
6. Add 100 μl colour reagent to each 
well, mix and read the absorbance 
at 570 nmand 690 nm 2-5 minutes 
after colour reagent addition.
7. Calculate the concentration of con-
trols and unknowns from the absor-
bance of the standard curve.24
B- Determination of total galactose 
(Galactose and galactose -1- phos-
phate) in dried blood spot using 
Quantitative Colorimetric Enzyme-
linked immunoassay test:
1. Punch 4 mm spots into microtitra-
tion plate wells. Pipette 10 μl pre-
cipitation reagents into each spot 
and allow to stand at room tempera-
ture for 10 minutes.
2. Pipette 100 μl of PBS or saline into 
each well and incubate at room 
temperature for 30 minutes. 
3. Pipette 40 μl standard/control into 
designate wells of a clean flat bot-
tom microtitration plate.
4. Transfer 40 μl of the blood spot 
eluate from the elution plate to the 
equivalent position of clean flat 
bottom microtitration plate and add 
100 μl working enzyme reagent.
5. Incubate for 30 minutes at room 
temperature.
6. Add 100 μl colour reagent to each 
well and read the absorbance at 
490/690 (dual wave length) 5 min-
utes after the addition of the colour 
reagent. The galactose concentra-
tion of the patient blood spot is 
calculated by reference to the ab-
sorbance values of the standards. 
A standard curve is constructed by 
blotting the absorbance at 490/690 
nm of the standards of vertical (Y) 
axis against galactose concentra-
tion of the standard curve on the 
horizontal (X) axis.24
RESULTS                                                        
The study included 3000 newborns. 
Their mean ages was 9.3 ± 2.43 days 
and mean weight was 3.1 ± 0.82 Kg. 
They were 1800 (60%) males and 1200 
(40%) females from Menoufiya Gover-
norate.
Phenylalanine level mg/dl Number                   % Total galactose  mg /dl Number           %
2   -   5   2183                        72.8 2       -   6   2528                 84.26
5  -    7   705                            23.5 6       -   8 450                   15
7  -  10  111                             3.7  8      -    12 21                    0.7
22      1                            0.033 19    1                     0.033
Total    3000                         100 Total 3000                100
Table 1: Phenylalanine and galactose levels among screened newborns.
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Table 2: Frequencies of Type of Labor, Gender and Consanguinity among the Screened Newborns.
Parameters Number %






















DISCUSSION                                       
Although newborn screening pro-
grammes started about 30 years ago in 
many countries, they are still lacking 
in a larger number of developing coun-
tries. The aim of such screening pro-
grammes is the prevention of disability 
and handicapping through simple tests 
and subsequent dietary treatment. As 
we are dealing with autosomal recessive 
disorders, the incidence is expected to 
be higher with increased consanguine-
ous marriages in our population. 
In our study, which included 3000 new-
borns, the mean age of sample collec-
tion was 9.3±2.43 days and the mean 
weight was 3.1±0.82 Kg. This is a rela-
tively high age for sample collection 
since; the screening programs collect 
the samples between 3rd - 5th day af-
ter delivery. Our study included 1800 
(60%) males and 1200 (40%) females. 
Male predominance has been encoun-
tered in other studies in our population. 
Positive consanguinity was found in 
57% of the samples.
The consanguinity rate might be higher 
than Prof. Temtamy’s study because in 
this study Menoufiya Governorate is 
the only source of the cases. This is a 
rural area with many villages following 
old customs this is the cause of the high 
consanguinity rate.  
64% were delivered by vaginal sections 
and 36% by cesarean delivery. The phe-
nylalanine level ranged from 1.2 – 22 
mg/dl with a mean of 3.19 ± 1.82 mg/
dl and the galactose level ranged from 
2 – 19 mg/dl with a mean of 3.34 ± 2.23 
mg/dl. 
This study showed that among the 3000 
neonates, 2183 (72.8. %) had phenyla-
lanine levels ranging from 2-5 mg /dl, 
705 (23.5%) had levels ranging from 
5-7 mg /dl, 111(3.7%) had levels rang-
ing from 7-10 mg/dl and one newborn 
(0.033%) had phenylalanine level of 22 
mg /dl which. The child appeared clini-
cally normal at the time of diagnosis. 
On repeating the test, it was found to 
be a true case Phenylketonuria (PKU). 
Those with a phenylalanine levels rang-
ing from 7-10 mg /dl (3.7%) were reas-
sayed again after one week and found 
to be transient hyperphenylalaninemia.
Hyperphenylalaninemia is a common 
finding in many previous studies. This 
is a transient condition, due to low birth 
weight or immature liver.
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By repeating the test after one week 
they should be all reverted to normal. 
Persistence of the high value or even 
rise in the phenylalanine level means 
a case of PKU which needs immediate 
management.
Galactosemia screening showed that 
2528 neonates (84.3%) with galactose 
levels ranging from 2-6 mg/dl, 450 
(15%) had levels ranging from 6-8 mg/
dl, 21(0.7%) had levels ranging from 
8-12 mg/dl and one newborn (0.033%) 
had galactose level of 19 mg /dl. The 
child was reassayed and found to be to 
true galactosemia with jumping in the 
total level to 120mg/dl. That newborn 
presented with mild jaundice which 
progressed to a picture similar to neona-
tal sepsis in the form of poor suckling, 
vomiting, hepatomegaly and failure to 
gain weight. All signs and symptoms 
improved on using lactose free milk.
This child was rescued by the study, be-
cause by the time of the appearance of 
the signs and symptoms the diagnosis 
was confirmed and dietary treatment 
with lactose free formula was immedi-
ately started. Otherwise, this newborn 
would have been treated as neonatal 
sepsis and might have died without a 
final diagnosis is reached.
As for the 21 cases, which had total ga-
lactose levels ranging from 8-12 mg/dl, 
they were all retested after one week 
from the first test and reverted to nor-
mal levels. Galactose is a very sensi-
tive liver marker. Any liver insult will 
increase the total galactose level. In a 
previous study on Galactosemia done 
on high risk Egyptian children with he-
patomegaly found that liver insult rais-
es the total galactose level, being a very 
sensitive marker to liver damage. 
The actual prevalence of PKU and ga-
lactosemia in this study were 1/3000. 
This is higher than that reported by 
Temtamy25, who found in a pilot study 
on 15,000 newborns in 3 governorates 
in Egypt that the incidence of PKU was 
1/ 7500 and of galactosemia 1/235025. 
Other studies were done in different 
populations to determine the prevalenc-
es of PKU and galactosemia as shown 
in (Table 3).
The latest consensus in Egypt showed 
that at least one million babies are born 
every year. Our study postulates that per 
year 333 newborns will have PKU and 
333 newborn have galactosemia. Both 
are treatable disorders and if diagnosed 
early handicapping caused by these two 
disorders could be prevented. The pre-
vention of such treatable disorders de-
pends on planning an efficient screen-
ing program; aware of the problems 
which might face our population. One 
of these problems is that the patients af-
ter delivary due to many social and cul-
tural habits and lack of awareness will 
not come again to the health service 
unit just for newborn screening, espe-
cially when the newborn looks healthy. 
There is variation between countries as 
to the exact time of screening  but there 
is general agreement to be during the 
first three weeks of life  as we did in our 
work and it is advisable to repeat the 
screening tests  if done during the first 3 
days of life. This high incidence in Me-
noufiya Governorate needs urgent plan-
ning of a neonatal screening program 
to save the expected affected numbers 
of diseased children and to find out the 
real prevalence of such disorders in 
this governorate with dense population 
number in the Delta region.  
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Table 3: Prevalence of PKU and Galactosemia by Different Authors.
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In the present study the only baby with 
true PKU (1/3000, 0.033%) had pheny-
lalanine level of 22 mg/dl. Clinically, 
he was a male baby of low birth weight 
2.05 kilogram. Otherwise, he appeared 
clinically normal. By follow up and re-
peating the test, he was cofirmed to be 
classical phenylketonuria and dietiti-
cally managed using phenylalanine free 
formula. His growth, physically and 
mentally went within the normal varia-
tion. 
Those with a phenylalanine levels rang-
ing from 8- 12 mg / dl (12 %) were test-
ed after two weeks and found to be to 
transient hyperphenyalaninemia. May 
be due to prematurety and immaturity 
of liver and others due to low birth 
weight. But on follow up and repeating 
the test they returned to normal levels 
within one month and needed no treat-
ment. All positive screening tests must 
be repeated by taking a new sample. If 
phenylalanine levels decreases, this is a 
case of transient hyperphenyalaninemia 
that does not need treatment. But if the 
case showed increase in the phenylala-
nine level, treatment must be instilled 
immediately.
There were highly significant negative 
associations between phenylalanine and 
age of newborns and weight. But posi-
tive associations with sex, being higher 
in males; type of labor either vaginal or 
cesarean being higher with vaginal de-
livery. This is attributed to higher num-
ber of vaginal deliveries than cesarean 
ones.
The results were in accordance with 
Abu Shahla 2004 who reported that ap-
proximately 60 % of PKU patients had 
consanguinous parents (first cousins), 
while 40 % showed no consanguinity.31 
Outcome data from the continuous fol-
low-up study showed that IQ of PKU 
patients was inversely correlated with 
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blood phenylalanine levels. Accord-
ingly, new treatment guidelines were 
issued that involved more stringent re-
striction of phenylalanine levels with 
the recommendation to start dietary 
treatment within 20 days postpartum.32
This result was in accordance with Fa-
teen, 2001 who screened 437 newborn 
and found that phenylalanine was sig-
nificantly higher in 5 newborns and ga-
lactose levels were high in 6 newborns 
and showed no significant change be-
tween cord blood sample and heel prick 
at third day of life but this high preva-
lence should be repeated at 2 weeks to 
exclude transient hyperphenylalanine-
mia in phenylalanine and galactose lev-
els33. In this study, we used quantitative 
colorimetric enzyme-linked immuno-
assay method which also was used by 
Schulze et al.34, who screened 400000 
newborn for PKU and have clearly 
shown  that enzyme assay is highly re-
liable, sensitive as compared to Guthri 
test34 or Fluorescence intensity (FI) 
which is influenced by high tempera-
ture, humidity, duration between sam-
pling and testing, and anemia. He stated 
that this method was useful, simple, 
and highly reliable for newborn mass 
screening of phenylketonuria.35
Prevalence of a disorder can only be 
estimated in large number of screened 
newborns. Still the high consanguinity 
rate is alarming and points to a high in-
cidence of autosomal recessive disease 
in Menoufiya Governorate found in this 
study.
Our study neither prove prevalence nor 
frequency, it is only a small population 
study. 
The whole Menoufiya Governorate 
should be screened before we can talk 
of prevalence or frequency. But the data 
obtained from this studied population 
sample is alarming and larger studies 
are needed to estimate the magnitude of 
the problem in each governorate sepa-
rately.   
Koch in 1999 reported the normal level 
of phenylalanine was 0.5 -1 mg/dl and 
some of the false negative PKU infants 
to the samples taken in first 24 hours of 
life. So PKU may be missed during ear-
ly newborn screening. He stated that:-
• Transient hyperphenylalaninemia 
due to delayed maturation of en-
zymes required for amino acid me-
tabolism was 4-10mg/dl
• Breast fed infants have a low phe-
nylalanine level than formula 
fed infants as breast milk contain 
12 -14 mg phenylalanine per ounce 
while formula fed 24 -28 mg phe-
nylalanine per ounce.
• Positive results were not problems 
as confirmatory repetition of PKU 
test is done and false positive re-
sults easily discovered.36
In  the present study, 84.26% 
(2528/3000) have galactose levels 
ranging from 2 - 6 mg/dl. Fifteen per-
cent (450/3000) had total galactose 
level ranging from 6-8 mg /dl, 0.7% 
(21/3000) had total galactose level 
ranging from 8-12 mg /dl and found to 
have transient elevated galactose. One 
patient 0.033% (1/3000) had total ga-
lactose level of 19 mg/dl which when 
repeated for confirmations was found to 
be 120 mg /dl. The child presented by 
mild jaundice and then progressed to a 
picture like neonatal sepsis, week suck-
ling, hepatosplenomegaly and failure to 
gain weight, which was improved on 
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galactose free diets. Cataract has devel-
oped inspite of the dietary treatment.
Dietary treatment: Babies with transient 
hypergalactosaemia were placed initial-
ly on a galactose-restricted formula. A 
galactose challenge test (blood exami-
nation after having about 100-150 ml 
normal milk) was performed and di-
etary restriction was lifted if their blood 
galactose level had normalized at three 
–four weeks of age.9
In our study the prevalence of true 
galactosemia was 1/3000 newborns 
which was higher than that remem-
bered by Nishimra, 2004 who reported 
the incidence of galactosemia neonatal 
screening to be 0.16% (100/63542), 
from them 0.15% had transient galac-
tosemia and 0.009% had persistennt ga-
lactosemia. Nishimra 2004 referred the 
etiology of transient galactosemia to 
delayed closure of the ductus venosus, 
heterozygous GALE (UDP-galactose 
4-epimerase) deficiency, and heterozy-
gous GALT (galactose-1-phosphate 
uridyltransferase) deficiency and due 
to undetermined causes. Also Nishimra 
2004 explained the etiology of persis-
tant galactosemia to hepatic haeman-
gioendothelioma with portohepatic ve-
nous shunt, patent ductus venosus with 
hypoplasia of the portal vein, citrin de-
ficiency, homozygous GALE deficiency 
and heterozygous GALE deficiency.11
False positive results in newborn 
screening for galactosemia are frequent 
and represent a substantial problem for 
screening programs. A common obser-
vation is the adverse affect that envi-
ronmental factors and sample handling 
procedures (practiced at the site of 
specimen collection or during specimen 
transport) may have effect on the galac-
tose level, resulting in low activity and 
in false positives.37
CONCLUSIONS                                          
The estimated prevalence of each of 
phenylketonuria and of galactosemia 
in this study is 1/3000 newborns, while 
in a previous study on 15000 Egyptian 
newborns it was 1/7500 for PKU and 
1/2350 for galactosemia.
Because early diagnosis and treatment 
can prevent the irreversible sequalae of 
the diseases and their complications, 
the prevention of such treatable disor-
ders depend on planning an efficient 
screening programme especially within 
the first three weeks after birth.
So, we recommend multicenter studies 
in different governorates in Egypt to 
estimate the real prevalence data and 
the magnitude of the problem in our 
country.
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